**10. Secukinumab**

In a multicenter, retrospective study of 15 BS patients with refractory manifestations secukinumab led to a complete or partial response in 90% during a follow-up of 18 months [23]. Interestingly, 60% of these patients had intestinal involvement, and they responded completely to secukinumab, an agent that paradoxically may induce or aggravate Crohn's disease. Thus, more research is necessary to understand the role of IL-17 in the pathogenesis of BD [5].
